Table 2.
Predictors of good prognosis in all patients with crescentic glomerulonephritis.
| Variables | Univariable | Multivariable | ||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Age | 1.01 (0.98–0.04) | 0.66 | ||
| Male | 1.03 (0.43–2.45) | 0.96 | ||
| ln(CRP) | 1.33 (1.00–1.76) | 0.047 | 1.34 (0.94–1.90) | 0.11 |
| ln(eGFR) | 3.01 (1.43–6.33) | 0.004 | 2.74 (1.01–7.43) | 0.048 |
| ln(uPCR) | 0.83 (0.28–2.45) | 0.73 | ||
| Vasculitis serology marker | 0.88 (0.34–2.30) | 0.79 | ||
| Histologic features | ||||
| Normal glomeruli (%) | 1.03 (1.01–1.05) | 0.01 | 0.99 (0.97–1.03) | 0.85 |
| Active crescents (%) | 1.00 (0.98–1.02) | 0.81 | ||
| Glomerular chronic change (%) | 0.98 (0.96–0.99) | 0.01 | 0.99 (0.96–1.01) | 0.35 |
| Tubular chronic change | 0.02 | |||
| IFTA 1 (versus IFTA 0) | 0.27 (0.05–1.40) | 0.12 | 0.24 (0.04–1.46) | 0.12 |
| IFTA 2 (versus IFTA 0) | 0.09 (0.01–0.58) | 0.01 | 0.15 (0.02–1.23) | 0.08 |
| IFTA 3 (versus IFTA 0) | 0.07 (0.01–0.51) | 0.009 | 0.11 (0.01–1.00) | 0.05 |
| Immunosuppressive treatment (reference: none)a | 0.11 | |||
| Treatment 1 | 3.00 (0.21–42.63) | 0.42 | ||
| Treatment 2 | 7.40 (0.77–70.77) | 0.08 | ||
| Treatment 3 | 2.50 (0.21–29.26) | 0.47 | ||
| CD 45 positive cells (%) | 0.99 (0.89–1.09) | 0.78 | ||
| CD 3 positive cells (%) | 1.02 (0.93–1.11) | 0.73 | ||
| CD 20 positive cells (%) | 0.98 (0.88–1.09) | 0.71 | ||
Logistic regression analyses were performed to determine the prognosis. Multivariable analyses were performed using variables with P < 0.1 in univariable analysis.
CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IFTA, interstitial fibrosis and tubular atrophy; ref, reference; OR, odds ratio; uPCR, urine protein to creatinine ratio.
aTreatment 1, 2, and 3: steroid alone, steroids with other immunosuppressants, and steroids with other immunosuppressants and plasmapheresis, respectively.